Table III.
Cox's proportional hazards regression models for overall survival (OS) and disease-free survival (DFS).
| OS | DFS | ||||||
|---|---|---|---|---|---|---|---|
| Variables | No. | RR | 95% CI | P-value | RR | 95% CI | P-value |
| Dense breast tissue | |||||||
| Negative | 97 | 0.647 | 0.138–3.424 | 0.647 | 1.175 | 0.816–1.692 | 0.387 |
| Positive | 70 | ||||||
| Nuclear grade | |||||||
| 1 | 10 | 0.068 | 0.006–0.759 | 0.029 | 1.086 | 0.694–1.699 | 0.719 |
| 2 | 99 | ||||||
| 3 | 58 | ||||||
| HistologicAL grade | |||||||
| 1 | 28 | 16.318 | 1.571–169.479 | 0.019 | 0.774 | 0.539–1.113 | 0.167 |
| 2 | 88 | ||||||
| 3 | 51 | ||||||
| Tumor size | |||||||
| T1 | 66 | 0.327 | 0.327–6.331 | 0.630 | 0.799 | 0.571–1.117 | 0.190 |
| T2 | 97 | ||||||
| T3 | 4 | ||||||
| LN metastasis | |||||||
| N0 | 92 | 3.140 | 1.255–7.857 | 0.014 | 1.218 | 0.986–1.505 | 0.068 |
| N1 | 44 | ||||||
| N2 | 20 | ||||||
| N3 | 11 | ||||||
| ER | |||||||
| Negative | 63 | 0.041 | 0.003–0.549 | 0.016 | 0.516 | 0.312–0.854 | 0.010 |
| Positive | 104 | ||||||
| PR | |||||||
| Negative | 95 | 6.908 | 0.552–86.498 | 0.134 | 0.820 | 0.526–1.277 | 0.379 |
| Positive | 72 | ||||||
| HER-2 | |||||||
| Negative | 122 | 0.940 | 0.177–4.995 | 0.940 | 0.882 | 0.581–1.340 | 0.557 |
| Positive | 45 | ||||||
| EGFR | |||||||
| Negative | 141 | 0.000 | 0.000 | 0.983 | 0.663 | 0.382–1.151 | 0.144 |
| Positive | 26 | ||||||
| CK 5/6 | |||||||
| Negative | 156 | 0.001 | 0.000 | 0.993 | 1.476 | 0.672–3.242 | 0.333 |
| Positive | 11 | ||||||
| Ki-67, % | |||||||
| Low (<10) | 123 | 7.922 | 0.460–136.514 | 0.154 | 1.345 | 0.891–2.030 | 0.158 |
| High (≥10) | 44 | ||||||
| IGF-1R | |||||||
| Low (0,1) | 104 | 1.093 | 0.176–6.795 | 0.924 | 0.928 | 0.637–1.353 | 0.698 |
| High (2,3) | 63 | ||||||
RR, relative risk; CI, confidence interval; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; CK, cytokeratin; IGF-1R, insulin-like growth factor 1 receptor.